Prescient Therapeutics – Investor Briefing

MELBOURNE Australia, 1 March 2022 – Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies to treat cancer, is pleased to announce that they will be holding an investor briefing on Thursday 3rd March at 1pm (AEDT).

To register for the investor briefing, visit this page:
https://prescienttherapeutics.investorportal.com.au/investor-briefing/

CEO and Managing Director, Steven Yatomi-Clarke, will provide a company update outlining Prescient's cutting-edge pipeline and the major catalysts that can be expected going forward.

A copy of the investor presentation to be presented is attached.

- Ends -

To stay updated with the latest company news and announcements, please update your details on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

Cell Therapy Enhancements: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound has previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer, with a Phase 1b/2 trial currently underway in relapsed and refractory AML.

The CEO and Managing Director of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter @PTX_AUS and LinkedIn.

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries:
Sophie Bradley – Reach Markets
+61 450 423 331
ir@reachmarkets.com.au

Media enquiries:
Andrew Geddes – CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website: Supplemental COVID-19 Risk Factors

IN FRONT OF THE BIGGEST WAVE IN ONCOLOGY

March 2022

DISCLAIMER AND SAFE HARBOR

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

The contents of this document are confidential information of Prescient. These contents are made available on a 'for your eyes only' basis to the person to whom it was sent by Prescient. The purpose of the disclosure is to facilitate commercial and confidential discussions between the disclosee and Prescient. It should not be forwarded without without the prior written consent of the Company.

Investment Highlights

World class pedigree.
We license from the best; and work with the best

Many shots on goal for substantial value creation

PTX-100: FIC Ras/Rho inhibitor in Ph1b expansion in PTCL

PTX-200: Akt inhibitor in Ph1b/2 AML

OmniCAR

Game-changing cell therapy platform



3 highly differentiated next-gen CAR-T programs:

1. **AML**
2. **Her2+ solid tumors**
3. **GBM**

An **enabling technology** for 3rd parties

Corporate Snapshot

ASX Ticker	**PTX**
Total Issued Capital	648 M shares
Listed Options	95.4 M
Unlisted Options	12.1 M
Share Price[1]	A$0.16 (US$0.12)
Market Capitalisation[1]	**A$103 M (US$74 M)**
Market Cap fully diluted[1]	**A$119 M (US$85 M)**
Cash Position[2]	**A$14.7M (US$11M)**
Top 20 Own	17%

1 - AS AT 28 FEB 2022
2 - AS AT 31 DEC 2021

Innovative Pipeline in Personalised Medicine



PTX-100

FIRST IN CLASS

RAS PATHWAY INHIBITOR

PTX-100 PHASE 1B SUMMARY

Excellent safety profile

- No serious safety issues related to PTX-100

Early clinical activity

- **Expected PFS of <4 months on SoC**
- PRs in 2 patients with aggressive refractory TCL
  1. **12 months**
  2. **17 months so far**

Professor H. Miles Prince, AM
Principal Investigator

Epworth



TCL: T CELL LYMPHOMA
PR: PARTIAL RESPONSE (REDUCTION OF DISEASE)
PFS: PROGRESSION FREE SURVIVAL (TIME UNTIL DISEASE WORSENS)
SOC: STANDARD OF CARE

PROGRESSING TO EXPANSION COHORT

- 8 – 12 patients with r/r T cell lymphoma (esp PTCL)
- Potential bridge to registration study
- Focussing on sweet spot in an area of considerable unmet need
- Shortest path to market

Case Study

- pralatrexate (Folotyn®)
- Approved for PTCL
  - 5,600 cases/year in US
- US$450,540 per patient, per year

PTX-200

NOVEL AKT INHIBITION

PHASE 1B TRIAL UNDERWAY: ACUTE MYELOID LEUKEMIA

- Building upon encouraging Phase 1 results with PTX-200 (monotherapy)
- PI Professor Jeff Lancet at Moffitt, Key Opinion Leader in AML
- 18 patients with cytarabine held constant at 200-400 mg/m^2 as continuous infusion
  - » 3 CRs so far
- Currently treating second cohort at 45 mg/m^2
- Granted Orphan Drug Designation by US FDA

Jeffrey E Lancet, M.D.
Principal Investigator

MOFFITT CANCER CENTER

Prescient Therapeutics

OmniCAR

Universal, Next Generation CAR-T

How does the CAR-T process work?

1.
Blood is collected from the patient

2.
T- Cells are separated and removed



3.
T-Cells are genetically altered to have special cancer-recognising receptors called Chimeric Antigen Receptor (CAR)

4.
Millions of CAR-T cells are grown

5.
Patient first receives Chemotherapy, and then the CAR – T cells are delivered to the patient

ENDPOINTSNEWS

Carl June: 'We can now conclude that CAR-T cells can actually cure patients'

Carl June (Brian Ach/Getty Images for TIME 100 Health Summit)

February 2, 2022 11:00 AM EST *Updated 12:00 PM* | R&D, Discovery

The Guardian

First patients of pioneering CAR T-cell therapy 'cured of cancer'

Cancer-killing cells still present 10 years on, with results suggesting therapy is a cure for certain blood cancers

Doug Olson still has cancer-killing cells 10 years after infusion. Photograph: AP

Penn is a pioneer and world leader in CAR-T

Prescient Therapeutics

Penn
University of Pennsylvania

NOVARTIS

- Novartis licensed CAR-T technology from Penn in 2012
- Kymriah® became the first CAR-T therapy approved by the FDA
- Used for certain blood cancers
- Cost of treatment in excess of $500,000 per treatment
- GlobalData forecasts Kymriah® sales to exceed US$1 billion in 2023

Key Challenges confronting the field of CAR-T

Prescient Therapeutics



Time and Cost

of delivering treatment

Safety

CAR-T can have serious safety concerns

No Control

Clinicians have no control of cells post infusion

Targets

Finding targets that work;

Antigen heterogeneity - esp. in solid tumours

Exhaustion

Persistent stimulation of CAR-Immune cells leads to exhaustion



Escape

Antigen loss leads to relapse

OmniCAR: flexible, modular CAR platform

Prescient Therapeutics



Penn
University of Pennsylvania

Associate Professor
Daniel J. Powell, Jr

Professor
Andrew Tsourkas

University of Oxford

OmniCAR can do what conventional CAR-T cannot

Conventional CAR-T

- Soldier with only one map
- Single weapon
- Only trained to hit one target
- Incapable of redirection
- No communication or control in the field

OmniCAR

Armed with **any weapon**

Including **several** at once

Can be given **any map**;
Multiple deployments

Full **communication** and **control** at all times, even mid-mission



Can direct against **any target**, including **simultaneous** targets

Send **images** back to base in real time

OmniCAR Platform Business Model

Next generation products in-house

- OmniCAR CD33/CLL1 for **AML**
- OmniCAR Her2 for **Solid Tumours**
- OmniCAR Her2/EGFRviii for **GBM**

Collaborate & license to third parties

- Potential partner based on **Targets**
- Potential partner based on **Specific Constructs**
- Potential partner based on **Cell Types**

Control: Dose-dependent CAR-T activity



- Ovarian cancer model, using anti-HER2 OmniCAR
- Loading more binder results in **proportionate killing** of cancer…
- …and **proportionate survival**
- **Lasting effects** even when cease dosing of binder



Powell, DJ et al, JACS; 2020

= dosing window of binder

OmniCAR cells can be Re-Armed



- OmniCAR T cells can be re-armed
- Re-arming results in **same levels and kinetics of cytotoxicity** as pre-armed
- Another example of **flexible** yet **predictable** activity

OmniCAR cells can be Redirected





- Rapid cytotoxicity to EGFRviii
- **Rapid switching and cytotoxicity** against HER2+ tumours upon administration of new binder
- OmniCAR cells can be **re-directed to different antigens** upon administration of a different SpyTagged binder **without new cells**

OmniCAR manufacturing advantages

Conventional CAR-T

Run 1

Run 2

Run 3

Run 4

Run 5

Run 6

Individual production runs for each CAR-T product

- Expensive ($'000k / run)
- Time consuming (22 days/run)
- Cannot redirect to new targets
- Prohibitive

E.g. 6 x ($$$$)

OmniCAR



Single production run for OmniCAR Auto T-cell

Subsequent administration of binders

- Much cheaper
- No time delay
- Redirect against multiple targets

E.g. (1*$$$$) + (6*$)

What's the Endgame?

The Apple Ecosystem

Personalized “Plug & Play” Cell Therapy Ecosystem

Prescient Therapeutics

Step 4:
OmniCAR- induced tumor killing with post-infusion control

Step 3:
Pair binders with OmniCAR cells
(T cells; NK; auto/allo)



Step 2:
Match patient’s antigens to corresponding binders

Step 1:
Patient sample to determine individual antigen profile

Summary

Key building blocks to PTX Future Value

Prescient Therapeutics

1

OmniCAR

- Next generation universal CAR platform
- AML
- Her2+ solid tumours
- GBM
- 3rd party opportunities

2

Cell Therapy Enhancements

- Enhancing current generation CAR-T
- Also applicable to next gen
- Collaboration with Peter Mac
- 100% ownership of Intellectual Property

3

Targeted therapies

- PTX-100
- PTX-200

Multiple catalysts in 2022



- Ongoing business development activities
- Continuing to build awareness among investors, clinicians and corporates
- PTX-100 expansion cohort full recruitment (~Q4 2022)
- Completion of enrolment in PTX-100 expansion cohort (Q2/3 2022)
- Announce further value-adding milestones for each OmniCAR program (several throughout 2022)
- Results for PTX-200 Ph1b AML trial (Q2 2022)
- Cell Therapy Enhancements come out of stealth mode (Q1/Q2 2022)
- Commence recruitment for PTX-100 expansion cohort in PTCL (imminent) – awaiting drug delivery

* Estimates only, given inherent uncertainty of biotech development

Compelling investment case!

World class pedigree.
We license from the best; and work with the best

Many shots on goal for substantial value creation

PTX-100: FIC Ras/Rho inhibitor in Ph1b expansion in PTCL

PTX-200: Akt inhibitor in Ph1b/2 AML

OmniCAR



Game-changing cell therapy platform

3 highly differentiated next-gen CAR-T programs:

1. **AML**
2. **Her2+ solid tumors**
3. **GBM**

An **enabling technology** for 3rd parties

Top-down analysis is sensible for investors

1

Biggest Market in Healthcare?

Oncology
US$145B*

2

Fastest growing area in oncology?

Cell Therapies (CAR-T)

3

Forefront of Cell Therapy?



Scalable
Controllable
Any target
Any immune cell

Prescient Therapeutics

*Statista.com; sales in 2019


Prescient
Therapeutics
Thank you!
ASX code: PTX
www.ptxtherapeutics.com